RNAZ
TransCode Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.06
−4.41%Aug 31, 2026, 12:05 UTC
TransCode Therapeutics announced the publication of a peer-reviewed article in Cancers reporting that its lead therapeutic candidate TTX-MC138 produced significant survival benefits in a preclinical model of breast cancer bone metastasis.
Source:Jul 22, 2026, 05:03 UTC
TransCode Therapeutics stockholders approved proposals to authorize the issuance of common stock and increase shares under the equity incentive plan at the reconvened annual meeting.
Source:Jun 3, 2026, 12:04 UTC
TransCode Therapeutics completed Phase 1a clinical trial of TTX-MC138 in metastatic cancer, reporting safety and disease stabilization data.
Source: